← FDA DRUG APPROVALS

FDA ANDA · ANDA202365

SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE

Sponsor: WATSON LABS INC

APPLICATION
ANDA202365
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDENone (Tentative Approval)
SITAGLIPTIN PHOSPHATE 50MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDENone (Tentative Approval)
SITAGLIPTIN PHOSPHATE 50MG, METFORMIN HYDROCHLORIDE 1000MG · TABLET · ORAL

Approval history

2015-10-30UNKNOWN · OriginalTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →